Author's posts
Navigating patient transitions following the withdrawal of Oxbryta
The withdrawal of Oxbryta (voxelotor) from global markets, announced by Pfizer after a recent data review revealed a rise in deaths and complications, has left sickle cell disease (SCD) patients in a precarious situation. The sudden nature of the annou…
